Melatonin’s Benefits and Risks as a Therapy for Sleep Disturbances in the Elderly: Current Insights

References

• Welz PS, Benitah SA. Molecular connections between circadian clocks and aging. J Mol Biol. 2020;432(12):3661–3679. doi:10.1016/J.JMB.2019.12.036
   PubMed Web of Science ®Google Scholar
• Fulop T, Larbi A, Pawelec G, et al. Immunology of aging: the birth of inflammaging. Clin Rev Allergy Immunol. 2021. doi:10.1007/S12016-021-08899-6
   PubMed Web of Science ®Google Scholar
• Borbély AA, Daan S, Wirz-Justice A, Deboer T. The two-process model of sleep regulation: a reappraisal. J Sleep Res. 2016;25(2):131–143. doi:10.1111/JSR.12371
   PubMed Web of Science ®Google Scholar
• Dawson D, Armstrong SM. Chronobiotics - Drugs that shift rhythms. Pharmacol Ther. 1996;69(1):15–36. doi:10.1016/0163-7258(95)02020-9
   PubMed Web of Science ®Google Scholar
• Skene DJ, Arendt J. Circadian rhythm sleep disorders in the blind and their treatment with melatonin. Sleep Med. 2007;8(6):651–655. doi:10.1016/j.sleep.2006.11.013
   PubMed Web of Science ®Google Scholar
• Emens JS, Eastman CI. Diagnosis and treatment of non-24-h sleep-wake disorder in the blind. Drugs. 2017;77(6):637–650. doi:10.1007/S40265-017-0707-3
   PubMed Web of Science ®Google Scholar
• Gobbi G, Comai S. Sleep well. Untangling the role of melatonin MT1 and MT2 receptors in sleep. J Pineal Res. 2019;66(3). doi:10.1111/JPI.12544
   PubMed Web of Science ®Google Scholar
• Auld F, Maschauer EL, Morrison I, Skene DJ, Riha RL. Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders. Sleep Med Rev. 2017;34:10–22. doi:10.1016/j.smrv.2016.06.005
   PubMed Web of Science ®Google Scholar
• Claustrat B, Leston J. Melatonin: physiological effects in humans. Neurochirurgie. 2015;61(2–3):77–84. doi:10.1016/J.NEUCHI.2015.03.002
   PubMed Web of Science ®Google Scholar
• Cardinali DP. Melatonin as a chronobiotic/cytoprotector: its role in healthy aging. Biol Rhythm Res. 2019;50(1):28–45. doi:10.1080/09291016.2018.1491200
   Web of Science ®Google Scholar
• Cirelli C, Tononi G. Is sleep essential? PLoS Biol. 2008;6(8):1605–1611. doi:10.1371/JOURNAL.PBIO.0060216
   Web of Science ®Google Scholar
• Hardeland R. Melatonin and circadian oscillators in aging–a dynamic approach to the multiply connected players. Interdiscip Top Gerontol. 2015;40:128–140. doi:10.1159/000364975
   PubMedGoogle Scholar
• Mitterling T, Högl B, Schönwald SV, et al. Sleep and respiration in 100 healthy caucasian sleepers–a polysomnographic study according to American academy of sleep medicine standards. Sleep. 2015;38(6):867–875. doi:10.5665/SLEEP.4730
   PubMed Web of Science ®Google Scholar
• Skeldon AC, Derks G, Dijk DJ. Modelling changes in sleep timing and duration across the lifespan: changes in circadian rhythmicity or sleep homeostasis? Sleep Med Rev. 2016;28:96–107. doi:10.1016/J.SMRV.2015.05.011
   PubMed Web of Science ®Google Scholar
• Cardinali DP. Autonomic Nervous System: Basic and Clinical Aspects. Springer, Cham; 2017. doi:10.1007/978-3-319-57571-1
   Google Scholar
• Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14(10):576–590. doi:10.1038/S41574-018-0059-4
   PubMed Web of Science ®Google Scholar
• Foley DJ, Monjan AA, Brown SL, Simonsick EM, Wallace RB, Blazer DG. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep. 1995;18(6):425–432. doi:10.1093/SLEEP/18.6.425
   PubMed Web of Science ®Google Scholar
• Ooms S, Overeem S, Besse K, Rikkert MO, Verbeek M, Claassen JAHR. Effect of 1 night of total sleep deprivation on cerebrospinal fluid β-amyloid 42 in healthy middle-aged men: a randomized clinical trial. JAMA Neurol. 2014;71(8):971–977. doi:10.1001/JAMANEUROL.2014.1173
   PubMed Web of Science ®Google Scholar
• Kang JE, Lim MM, Bateman RJ, et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326(5955):1005–1007. doi:10.1126/SCIENCE.1180962
   PubMed Web of Science ®Google Scholar
• Iliff JJ, Wang M, Liao Y, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med. 2012;4(147). doi:10.1126/scitranslmed.3003748
   PubMed Web of Science ®Google Scholar
• Jessen NA, Munk ASF, Lundgaard I, Nedergaard M. The glymphatic system: a beginner’s guide. Neurochem Res. 2015;40(12):2583–2599. doi:10.1007/s11064-015-1581-6
   PubMed Web of Science ®Google Scholar
• Braun M, Iliff JJ. The impact of neurovascular, blood-brain barrier, and glymphatic dysfunction in neurodegenerative and metabolic diseases. Int Rev Neurobiol. 2020;154:413–436. doi:10.1016/bs.irn.2020.02.006
   PubMed Web of Science ®Google Scholar
• Leston J, Harthé C, Mottolese C, Mertens P, Sindou M, Claustrat B. Is pineal melatonin released in the third ventricle in humans? A study in movement disorders. Neurochirurgie. 2015;61(2–3):85–89. doi:10.1016/J.NEUCHI.2013.04.004
   PubMed Web of Science ®Google Scholar
• Reiter RJ, Sharma R, Rosales-Corral S, et al. Melatonin in ventricular and subarachnoid cerebrospinal fluid: its function in the neural glymphatic network and biological significance for neurocognitive health. Biochem Biophys Res Commun. 2022;605:70–81. doi:10.1016/J.BBRC.2022.03.025
   PubMed Web of Science ®Google Scholar
• Xie X, Ding D, Bai D, et al. Melatonin biosynthesis pathways in nature and its production in engineered microorganisms. Synth Syst Biotechnol. 2022;7(1):544–553. doi:10.1016/J.SYNBIO.2021.12.011
   PubMed Web of Science ®Google Scholar
• Cardinali DP, Lynch HJ, Wurtman RJ. Binding of melatonin to human and rat plasma proteins. Endocrinology. 1972;91(5):1213–1218. doi:10.1210/ENDO-91-5-1213
   PubMed Web of Science ®Google Scholar
• Moroni I, Garcia-Bennett A, Chapman J, Grunstein RR, Gordon CJ, Comas M. Pharmacokinetics of exogenous melatonin in relation to formulation, and effects on sleep: a systematic review. Sleep Med Rev. 2021;57. doi:10.1016/j.smrv.2021.101431
   PubMed Web of Science ®Google Scholar
• Hardeland R. Melatonin metabolism in the central nervous system. Curr Neuropharmacol. 2010;8(3):168–181. doi:10.2174/157015910792246244
   PubMed Web of Science ®Google Scholar
• Suofu Y, Li W, Jean-Alphonse FG, et al. Dual role of mitochondria in producing melatonin and driving GPCR signaling to block cytochrome c release. Proc Natl Acad Sci U S A. 2017;114(38):E7997–E8006. doi:10.1073/PNAS.1705768114
   PubMed Web of Science ®Google Scholar
• Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res. 2007;42(1):28–42. doi:10.1111/j.1600-079X.2006.00407.x
   PubMed Web of Science ®Google Scholar
• Dubocovich ML, Delagrange P, Krause DN, Sugden D, Cardinali DP, Olcese J. International union of basic and clinical pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev. 2010;62(3). doi:10.1124/pr.110.002832
   PubMed Web of Science ®Google Scholar
• Ng KY, Leong MK, Liang H, Paxinos G. Melatonin receptors: distribution in mammalian brain and their respective putative functions. Brain Struct Funct. 2017;222(7):2921–2939. doi:10.1007/S00429-017-1439-6
   PubMed Web of Science ®Google Scholar
• Liu C, Weaver DR, Jin X, et al. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron. 1997;19(1):91–102. doi:10.1016/S0896-6273(00)80350-5
   PubMed Web of Science ®Google Scholar
• Lavie P. Melatonin: role in gating nocturnal rise in sleep propensity. J Biol Rhythms. 1997;12(6):657–665. doi:10.1177/074873049701200622
   PubMed Web of Science ®Google Scholar
• Clarke IJ, Caraty A. Kisspeptin and seasonality of reproduction. Adv Exp Med Biol. 2013;784:411–430. doi:10.1007/978-1-4614-6199-9_19
   PubMed Web of Science ®Google Scholar
• Lax P, Ortuño-Lizarán I, Maneu V, Vidal-Sanz M, Cuenca N. Photosensitive melanopsin-containing retinal ganglion cells in health and disease: implications for circadian rhythms. Int J Mol Sci. 2019;20(13). doi:10.3390/IJMS20133164
   PubMed Web of Science ®Google Scholar
• Lewy A. Clinical implications of the melatonin phase response curve. J Clin Endocrinol Metab. 2010;95(7):3158–3160. doi:10.1210/jc.2010-1031
   PubMed Web of Science ®Google Scholar
• Acuña-Castroviejo D, Escames G, Venegas C, et al. Extrapineal melatonin: sources, regulation, and potential functions. Cell Mol Life Sci. 2014;71(16):2997–3025. doi:10.1007/s00018-014-1579-2
   PubMed Web of Science ®Google Scholar
• Tan DX, Reiter RJ. Mitochondria: the birth place, battle ground and the site of melatonin metabolism in cells. Melatonin Res. 2019;2(1):44–66. doi:10.32794/mr11250011
   Google Scholar
• Hardeland R. Melatonin and inflammation—Story of a double-edged blade. J Pineal Res. 2018;65(4). doi:10.1111/jpi.12525
   PubMed Web of Science ®Google Scholar
• Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013;8(5). doi:10.1371/JOURNAL.PONE.0063773
   PubMed Web of Science ®Google Scholar
• Chen S, Shi LG, Liang F, et al. Exogenous melatonin for delirium prevention: a meta-analysis of randomized controlled trials. Mol Neurobiol. 2016;53(6):4046–4053. doi:10.1007/S12035-015-9350-8
   PubMed Web of Science ®Google Scholar
• Palagini L, Manni R, Aguglia E, et al. Expert opinions and consensus recommendations for the evaluation and management of insomnia in clinical practice: joint statements of five Italian scientific societies. Front Psychiatry. 2020;11. doi:10.3389/FPSYT.2020.00558
   PubMed Web of Science ®Google Scholar
• Palagini L, Manni R, Aguglia E, et al. International expert opinions and recommendations on the use of melatonin in the treatment of insomnia and circadian sleep disturbances in adult neuropsychiatric disorders. Front Psychiatry. 2021;12. doi:10.3389/FPSYT.2021.688890
   PubMed Web of Science ®Google Scholar
• Wilson S, Anderson K, Baldwin D, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update. J Psychopharmacol. 2019;33(8):923–947. doi:10.1177/0269881119855343
   PubMed Web of Science ®Google Scholar
• Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010;24(11):1577–1600. doi:10.1177/0269881110379307
   PubMed Web of Science ®Google Scholar
• Duffy JF, Wang W, Ronda JM, Czeisler CA. High dose melatonin increases sleep duration during nighttime and daytime sleep episodes in older adults. J Pineal Res. 2022;e12801. doi:10.1111/jpi.12801
   PubMed Web of Science ®Google Scholar
• Burgess HJ, Emens JS. Drugs used in circadian sleep-wake rhythm disturbances. Sleep Med Clin. 2020;15(2):301–310. doi:10.1016/J.JSMC.2020.02.015
   PubMed Web of Science ®Google Scholar
• Moore RY, Speh JC. GABA is the principal neurotransmitter of the circadian system. Neurosci Lett. 1993;150(1):112–116. doi:10.1016/0304-3940(93)90120-A
   PubMed Web of Science ®Google Scholar
• Neikrug AB, Ancoli-Israel S. Sleep disorders in the older adult - a mini-review. Gerontology. 2010;56(2):181–189. doi:10.1159/000236900
   PubMed Web of Science ®Google Scholar
• Goswami N, Abulafia C, Vigo D, Moser M, Cornelissen G, Cardinali D. Falls risk, circadian rhythms and melatonin: current perspectives. Clin Interv Aging. 2020;15:2165–2174. doi:10.2147/CIA.S283342
   PubMed Web of Science ®Google Scholar
• Boyle N, Naganathan V, Cumming RG. Medication and falls: risk and optimization. Clin Geriatr Med. 2010;26(4):583–605. doi:10.1016/J.CGER.2010.06.007
   PubMed Web of Science ®Google Scholar
• Clay E, Falissard B, Moore N, Toumi M. Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and z-drugs consumption in nine European countries. Eur J Clin Pharmacol. 2013;69(4):1–10. doi:10.1007/s00228-012-1424-1
   PubMed Web of Science ®Google Scholar
• Antón-Tay F. Melatonin: effects on brain function. Adv Biochem Psychopharmacol. 1974;11:315–324.
   PubMedGoogle Scholar
• Rudeen PK, Philo RC, Symmes SK. Antiepileptic effects of melatonin in the pinealectomized Mongolian gerbil. Epilepsia. 1980;21(2):149–154. doi:10.1111/J.1528-1157.1980.TB04056.X
   PubMed Web of Science ®Google Scholar
• Albertson TE, Peterson SL, Stark LG, Lakin ML, Winters WD. The anticonvulsant properties of melatonin on kindled seizures in rats. Neuropharmacology. 1981;20(1):61–66. doi:10.1016/0028-3908(81)90043-5
   PubMed Web of Science ®Google Scholar
• Forcelli PA, Soper C, Duckles A, Gale K, Kondratyev A. Melatonin potentiates the anticonvulsant action of phenobarbital in neonatal rats. Epilepsy Res. 2013;107(3):217–223. doi:10.1016/J.EPLEPSYRES.2013.09.013
   PubMed Web of Science ®Google Scholar
• Borowicz KK, Kamiński R, Gasior M, Kleinrok Z, Czuczwar SJ. Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. Eur Neuropsychopharmacol. 1999;9(3):185–190. doi:10.1016/S0924-977X(98)00022-4
   PubMed Web of Science ®Google Scholar
• Golombek DA, PéVet P, Cardinali DP. Melatonin effects on behavior: possible mediation by the central GABAergic system. Neurosci Biobehav Rev. 1996;20(3). doi:10.1016/0149-7634(95)00052-6
   PubMed Web of Science ®Google Scholar
• Golombek DA, Escolar E, Cardinali DP. Melatonin-induced depression of locomotor activity in hamsters: time-dependency and inhibition by the central-type benzodiazepine antagonist Ro 15-1788. Physiol Behav. 1991;49(6). doi:10.1016/0031-9384(91)90336-M
   PubMed Web of Science ®Google Scholar
• Golombek DA, Duque DF, de Brito Sánchez MG, Burin L, Cardinali DP. Time-dependent anticonvulsant activity of melatonin in hamsters. Eur J Pharmacol. 1992;210(3). doi:10.1016/0014-2999(92)90412-W
   PubMed Web of Science ®Google Scholar
• Muñoz-Hoyos A, Sánchez-Forte M, Molina-Carballo A, et al. Melatonin’s role as an anticonvulsant and neuronal protector: experimental and clinical evidence. J Child Neurol. 1998;13(10):501–509. doi:10.1177/088307389801301007
   PubMed Web of Science ®Google Scholar
• Fenoglio-Simeone K, Mazarati A, Sefidvash-Hockley S, et al. Anticonvulsant effects of the selective melatonin receptor agonist ramelteon. Epilepsy Behav. 2009;16(1):52–57. doi:10.1016/J.YEBEH.2009.07.022
   PubMed Web of Science ®Google Scholar
• Golombek DA, Martini M, Cardinali DP. Melatonin as an anxiolytic in rats: time dependence and interaction with the central GABAergic system. Eur J Pharmacol. 1993;237(2–3). doi:10.1016/0014-2999(93)90273-K
   PubMed Web of Science ®Google Scholar
• Golombek DA, Escolar E, Burin LJ, de Brito Sánchez MG, Cardinali DP. Time-dependent melatonin analgesia in mice: inhibition by opiate or benzodiazepine antagonism. Eur J Pharmacol. 1991;194(1). doi:10.1016/0014-2999(91)90119-B
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Pandi-Perumal SR, Spence DW, et al. Potential use of melatonergic drugs in analgesia: mechanisms of action. Brain Res Bull. 2010;81(4–5). doi:10.1016/j.brainresbull.2009.12.001
   PubMed Web of Science ®Google Scholar
• Rosenstein RE, Cardinali DP. Central gabaergic mechanisms as targets for melatonin activity in brain. Neurochem Int. 1990;17(3). doi:10.1016/0197-0186(90)90019-P
   PubMed Web of Science ®Google Scholar
• Niles LP, Peace CH. Allosteric modulation of t-[35S]butylbicyclophosphorothionate binding in rat brain by melatonin. Brain Res Bull. 1990;24(4):635–638. doi:10.1016/0361-9230(90)90171-U
   PubMed Web of Science ®Google Scholar
• Stankov B, Biella G, Panara C, et al. Melatonin signal transduction and mechanism of action in the central nervous system: using the rabbit cortex as a model. Endocrinology. 1992;130(4):2152–2159. doi:10.1210/ENDO.130.4.1312448
   PubMed Web of Science ®Google Scholar
• Wan Q, Man HY, Liu F, et al. Differential modulation of GABAA receptor function by Mel1a and Mel1b receptors. Nat Neurosci. 1999;2(5):401–403. doi:10.1038/8062
   PubMed Web of Science ®Google Scholar
• Shibata S, Cassone VM, Moore RY. Effects of melatonin on neuronal activity in the rat suprachiasmatic nucleus in vitro. Neurosci Lett. 1989;97(1–2):140–144. doi:10.1016/0304-3940(89)90153-5
   PubMed Web of Science ®Google Scholar
• Cheng XP, Sun H, Ye ZY, Zhou JN. Melatonin modulates the GABAergic response in cultured rat hippocampal neurons. J Pharmacol Sci. 2012;119(2):177–185. doi:10.1254/JPHS.11183FP
   PubMed Web of Science ®Google Scholar
• Fainstein I, Bonetto AJ, Brusco LI, Cardinali DP. Effects of melatonin in elderly patients with sleep disturbance: a pilot study. Curr Ther Res Clin Exp. 1997;58(12). doi:10.1016/S0011-393X(97)80066-5
   Web of Science ®Google Scholar
• Siegrist C, Benedetti C, Orlando A, et al. Lack of changes in serum prolactin, FSH, TSH, and estradiol after melatonin treatment in doses that improve sleep and reduce benzodiazepine consumption in sleep-disturbed, middle-aged, and elderly patients. J Pineal Res. 2001;30(1). doi:10.1034/j.1600-079X.2001.300105.x
   PubMed Web of Science ®Google Scholar
• Garfinkel D, Zisapel N, Wainstein J, Laudon M. Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach. Arch Intern Med. 1999;159(20):2456–2460. doi:10.1001/ARCHINTE.159.20.2456
   PubMed Web of Science ®Google Scholar
• Hajak G, Lemme K, Zisapel N. Lasting treatment effects in a postmarketing surveillance study of prolonged-release melatonin. Int Clin Psychopharmacol. 2015;30(1):36–42. doi:10.1097/YIC.0000000000000046
   PubMed Web of Science ®Google Scholar
• Kunz D, Bineau S, Maman K, Milea D, Toumi M. Benzodiazepine discontinuation with prolonged-release melatonin: hints from a German longitudinal prescription database. Expert Opin Pharmacother. 2012;13(1):9–16. doi:10.1517/14656566.2012.638284
   PubMed Web of Science ®Google Scholar
• Dagan Y, Zisapel N, Nof D, Laudon M, Atsmon J. Rapid reversal of tolerance to benzodiazepine hypnotics by treatment with oral melatonin: a case report. Eur Neuropsychopharmacol. 1997;7(2):157–160. doi:10.1016/S0924-977X(96)00381-1
   PubMed Web of Science ®Google Scholar
• Furio AM, Brusco LI, Cardinali DP. Possible therapeutic value of melatonin in mild cognitive impairment: a retrospective study. J Pineal Res. 2007;43(4). doi:10.1111/j.1600-079X.2007.00491.x
   PubMed Web of Science ®Google Scholar
• Baandrup L, Fagerlund B, Glenthoj B. Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo. Eur Arch Psychiatry Clin Neurosci. 2017;267(2):163–171. doi:10.1007/S00406-016-0711-8
   PubMed Web of Science ®Google Scholar
• Baandrup L, Glenthøj BY, Jennum PJ. Objective and subjective sleep quality: melatonin versus placebo add-on treatment in patients with schizophrenia or bipolar disorder withdrawing from long-term benzodiazepine use. Psychiatry Res. 2016;240:163–169. doi:10.1016/j.psychres.2016.04.031
   PubMed Web of Science ®Google Scholar
• Vissers FHJA, Knipschild PG, Crebolder HFJM. Is melatonin helpful in stopping the long-term use of hypnotics? A discontinuation trial. Pharm World Sci. 2007;29(6):641–646. doi:10.1007/S11096-007-9118-Y
   PubMed Web of Science ®Google Scholar
• Morera-Fumero AL, Fernandez-Lopez L, Abreu-Gonzalez P. Melatonin and melatonin agonists as treatments for benzodiazepines and hypnotics withdrawal in patients with primary insomnia. A systematic review. Drug Alcohol Depend. 2020;212. doi:10.1016/J.DRUGALCDEP.2020.107994
   PubMed Web of Science ®Google Scholar
• Baandrup L, Ebdrup BH, Rasmussen JO, Lindschou J, Gluud C, Glenthøj BY. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst Rev. 2018;3(3). doi:10.1002/14651858.CD011481.PUB2
   PubMed Web of Science ®Google Scholar
• Stephens ER, Sarangi A, Gude J. Short sleep duration and dementia: a narrative review. ProcBayl Univ Med Cent. 2022;35(3):328–331. doi:10.1080/08998280.2022.2026123
   PubMedGoogle Scholar
• Benca R, Herring WJ, Khandker R, Qureshi ZP. Burden of insomnia and sleep disturbances and the impact of sleep treatments in patients with probable or possible alzheimer’s disease: a structured literature review. J Alzheimers Dis. 2022;86(1):83–109. doi:10.3233/JAD-215324
   PubMed Web of Science ®Google Scholar
• Guu T, Aarsland D, Ffytche D. Light, sleep-wake rhythm, and behavioural and psychological symptoms of dementia in care home patients: revisiting the sundowning syndrome. Int J Geriatr Psychiatry. 2022;37(5). doi:10.1002/GPS.5712
   PubMed Web of Science ®Google Scholar
• Riemersma-van Der Lek RF, Swaab DF, Twisk J, Hol EM, Hoogendijk WJG, van Someren EJW. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA. 2008;299(22):2642–2655. doi:10.1001/jama.299.22.2642
   PubMed Web of Science ®Google Scholar
• Brusco LI, Marquez M, Cardinali DP. Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer’s disease. Neuro Endocrinol Letter. 1998;19(3):39–42.
   Google Scholar
• Liu RY, Zhou JN, van Heerikhuize J, Hofman MA, Swaab DF. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer’s disease, and apolipoprotein E-epsilon4/4 genotype. J Clin Endocrinol Metab. 1999;84(1):323–327. doi:10.1210/JCEM.84.1.5394
   PubMed Web of Science ®Google Scholar
• Şirin FB, Kumbul Doğuc D, Vural H, et al. Plasma 8-isoPGF2α and serum melatonin levels in patients with minimal cognitive impairment and Alzheimer disease. Turk J Med Sci. 2015;45(5):1073–1077. doi:10.3906/SAG-1406-134
   PubMed Web of Science ®Google Scholar
• Allan CL, Behrman S, Ebmeier KP, Valkanova V. Diagnosing early cognitive decline-When, how and for whom? Maturitas. 2017;96:103–108. doi:10.1016/J.MATURITAS.2016.11.018
   PubMed Web of Science ®Google Scholar
• Sumsuzzman DM, Choi J, Jin Y, Hong Y. Neurocognitive effects of melatonin treatment in healthy adults and individuals with Alzheimer’s disease and insomnia: a systematic review and meta-analysis of randomized controlled trials. Neurosci Biobehav Rev. 2021;127:459–473. doi:10.1016/J.NEUBIOREV.2021.04.034
   PubMed Web of Science ®Google Scholar
• Wang YY, Zheng W, Ng CH, Ungvari GS, Wei W, Xiang YT. Meta-analysis of randomized, double-blind, placebo-controlled trials of melatonin in Alzheimer’s disease. Int J Geriatr Psychiatry. 2017;32(1):50–57. doi:10.1002/GPS.4571
   PubMed Web of Science ®Google Scholar
• Xu J, Wang LL, Dammer EB, et al. Melatonin for sleep disorders and cognition in dementia: a meta-analysis of randomized controlled trials. Am J Alzheimers Dis Other Demen. 2015;30(5):439–447. doi:10.1177/1533317514568005
   PubMed Web of Science ®Google Scholar
• Zhang Q, Gao F, Zhang S, Sun W, Li Z. Prophylactic use of exogenous melatonin and melatonin receptor agonists to improve sleep and delirium in the intensive care units: a systematic review and meta-analysis of randomized controlled trials. Sleep Breath. 2019;23(4):1059–1070. doi:10.1007/S11325-019-01831-5
   PubMed Web of Science ®Google Scholar
• Cardinali DP, Vigo DE, Olivar N, Vidal MF, Brusco LI. Melatonin therapy in patients with Alzheimer’s disease. Antioxidants. 2014;3(2). doi:10.3390/antiox3020245
   Google Scholar
• Cardinali DP, Vigo DE, Olivar N, Vidal MF, Furio AM, Brusco LI. Therapeutic application of melatonin in mild cognitive impairment. Am J Neurodegener Dis. 2012;1(3):280.
   PubMedGoogle Scholar
• Ma H, Yan J, Sun W, Jiang M, Zhang Y. Melatonin Treatment for Sleep Disorders in Parkinson’s Disease: a Meta-Analysis and Systematic Review. Front Aging Neurosci. 2022;14. doi:10.3389/FNAGI.2022.784314
   Web of Science ®Google Scholar
• Dauvilliers Y, Schenck CH, Postuma RB, et al. REM sleep behaviour disorder. Nat Rev Dis Primers. 2018;4(1). doi:10.1038/s41572-018-0016-5
   PubMed Web of Science ®Google Scholar
• Pérez-Lloret S, Cardinali DP. Melatonin as a chronobiotic and cytoprotective agent in parkinson’s disease. Front Pharmacol. 2021;12:650597. doi:10.3389/fphar.2021.650597
   PubMed Web of Science ®Google Scholar
• Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010;6(1):85–95. doi:10.5664/jcsm.27717
   PubMed Web of Science ®Google Scholar
• Gilat M, Marshall NS, Testelmans D, Buyse B, Lewis SJG. A critical review of the pharmacological treatment of REM sleep behavior disorder in adults: time for more and larger randomized placebo-controlled trials. J Neurol. 2022;269(1):125–148. doi:10.1007/S00415-020-10353-0
   PubMed Web of Science ®Google Scholar
• Kunz D, Stotz S, Bes F. Treatment of isolated REM sleep behavior disorder using melatonin as a chronobiotic. J Pineal Res. 2021;71(2). doi:10.1111/JPI.12759
   PubMed Web of Science ®Google Scholar
• Kunz D, Bes F. Twenty years after: another case report of melatonin effects on rem sleep behavior disorder, using serial dopamine transporter imaging. Neuropsychobiology. 2017;76(2):100–104. doi:10.1159/000488893
   PubMed Web of Science ®Google Scholar
• Sugden D. Psychopharmacological effects of melatonin in mouse and rat. J Pharmacol Exp Ther. 1983;227(3):587–591.
   PubMed Web of Science ®Google Scholar
• Galley HF, Lowes DA, Allen L, Cameron G, Aucott LS, Webster NR. Melatonin as a potential therapy for sepsis: a Phase I dose escalation study and an ex vivo whole blood model under conditions of sepsis. J Pineal Res. 2014;56(4):427–438. doi:10.1111/jpi.12134
   PubMed Web of Science ®Google Scholar
• Andersen LPH, Gögenur I, Rosenberg J, Reiter RJ. The safety of melatonin in humans. Clin Drug Investig. 2016;36(3):169–175. doi:10.1007/S40261-015-0368-5
   PubMed Web of Science ®Google Scholar
• Cardinali DP. Are melatonin doses employed clinically adequate for melatonin-induced cytoprotection? Melatonin Res. 2019;2(2):106–132. doi:10.32794/mr11250025
   Google Scholar
• Li J, Somers VK, Xu H, Lopez-Jimenez F, Covassin N. Trends in use of melatonin supplements among us adults, 1999–2018. JAMA. 2022;327(5):483–485. doi:10.1001/JAMA.2021.23652
   PubMed Web of Science ®Google Scholar
• Clarke TC, Black LI, Stussman BJ, Barnes PM, Nahin RL. Trends in the use of complementary health approaches among adults: United States, 2002–2012. Natl Health Stat Report. 2015;79:1.
   PubMedGoogle Scholar
• Goldstein CA, Burgess HJ. Hit or miss: the use of melatonin supplements. J Clin Sleep Med. 2020;16(1):29S–30S. doi:10.5664/JCSM.8896
   PubMed Web of Science ®Google Scholar
• Erland LAE, Saxena PK. Melatonin natural health products and supplements: presence of serotonin and significant variability of melatonin content. J Clin Sleep Med. 2017;13(2):275–281. doi:10.5664/jcsm.6462
   PubMed Web of Science ®Google Scholar
• Peketi P, Zimmerman S, Palmertree S, Wretman CJ, Preisser JS, Sloane PD. Melatonin prescribing in assisted living. J Am Med Dir Assoc. 2021. doi:10.1016/J.JAMDA.2021.10.005
   PubMed Web of Science ®Google Scholar
• Li C, Ma D, Li M, et al. The therapeutic effect of exogenous melatonin on depressive symptoms: a systematic review and meta-analysis. Front Psychiatry. 2022;13. doi:10.3389/FPSYT.2022.737972
   Web of Science ®Google Scholar
• Foley HM, Steel AE. Adverse events associated with oral administration of melatonin: a critical systematic review of clinical evidence. Complement Ther Med. 2019;42:65–81. doi:10.1016/J.CTIM.2018.11.003
   PubMed Web of Science ®Google Scholar
• Besag FMC, Vasey MJ, Lao KSJ, Wong ICK. Adverse events associated with melatonin for the treatment of primary or secondary sleep disorders: a systematic review. CNS Drugs. 2019;33(12):1167–1186. doi:10.1007/s40263-019-00680-w
   PubMed Web of Science ®Google Scholar
• Menczel Schrire Z, Phillips CL, Chapman JL, et al. Safety of higher doses of melatonin in adults: a systematic review and meta-analysis. J Pineal Res. 2022;72(2). doi:10.1111/JPI.12782
   PubMed Web of Science ®Google Scholar
• Lelak K, Vohra V, Neuman MI, Toce MS, Sethuraman U. Pediatric melatonin ingestions — United States, 2012–2021. MMWR Morb Mortal Wkly Rep. 2022;71(22):725–729. doi:10.15585/MMWR.MM7122A1
   PubMed Web of Science ®Google Scholar
• Moon E, Partonen T, Beaulieu S, Linnaranta O. Melatonergic agents influence the sleep-wake and circadian rhythms in healthy and psychiatric participants: a systematic review and meta-analysis of randomized controlled trials. Neuropsychopharmacology. 2022;47(8):1523–1536. doi:10.1038/S41386-022-01278-5
   PubMed Web of Science ®Google Scholar
• Wang L, Pan Y, Ye C, et al. A network meta-analysis of the long- and short-term efficacy of sleep medicines in adults and older adults. Neurosci Biobehav Rev. 2021;131:489–496. doi:10.1016/J.NEUBIOREV.2021.09.035
   PubMed Web of Science ®Google Scholar
• Chan V, Wang L, Allman‐farinelli M. Efficacy of functional foods, beverages and supplements claiming to alleviate air travel symptoms: systematic review and meta‐analysis. Nutrients. 2021;13(3):1–24. doi:10.3390/nu13030961
   Web of Science ®Google Scholar
• Cuomo BM, Vaz S, Lee EAL, Thompson C, Rogerson JM, Falkmer T. Effectiveness of sleep-based interventions for children with autism spectrum disorder: a meta-synthesis. Pharmacotherapy. 2017;37(5):555–578. doi:10.1002/PHAR.1920
   PubMed Web of Science ®Google Scholar
• Schröder CM, Broquère MA, Claustrat B, et al. Therapeutic approaches for sleep and rhythms disorders in children with ASD. Encephale. 2022;48(3):294–303. doi:10.1016/j.encep.2021.08.005
   PubMed Web of Science ®Google Scholar
• Masters A, Pandi-Perumal SR, Seixas A, Girardin JL, Mcfarlane SI. Melatonin, the hormone of darkness: from sleep promotion to ebola treatment. Brain Disord Ther. 2014;4. doi:10.4172/2168-975X.1000151
   PubMedGoogle Scholar
• Williamson BL, Tomlinson AJ, Naylor S, Gleich GJ. Contaminants in commercial preparations of melatonin. Mayo Clin Proc. 1997;72(11):1094–1095. doi:10.1016/S0025-6196(11)63555-6
   PubMed Web of Science ®Google Scholar
• Grigg-Damberger MM, Ianakieva D. Poor quality control of over-the-counter melatonin: what they say is often not what you get. J Clin Sleep Med. 2017;13(2):163–165. doi:10.5664/JCSM.6434
   PubMed Web of Science ®Google Scholar
• Papagiannidou E, Skene DJ, Ioannides C. Potential drug interactions with melatonin. Physiol Behav. 2014;131:17–24. doi:10.1016/J.PHYSBEH.2014.04.016
   PubMed Web of Science ®Google Scholar
• Arendt J. Safety of melatonin in long-term use (?). J Biol Rhythms. 1997;12(6):673–681. doi:10.1177/074873049701200624
   PubMed Web of Science ®Google Scholar